NCT02857868View on ClinicalTrials.gov

A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 3, 2016

Primary Completion Date

July 20, 2017

Study Completion Date

July 20, 2017

Conditions
Hepatic Impairment
Interventions
DRUG

ABL001

Trial Locations (3)

32809

Orlando Clinical Research Center, Orlando

33136

University of Miami / Clinical Research Services, Inc., Miami

55404

DaVita Clinical Research, Minneapolis

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY